817 results about "Aminopyridines" patented technology

2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

The present invention provides a compound which has an effect of inhibiting amyloid-β production and is useful as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-β proteins. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:

wherein A is optionally substituted carbocyclic diyl or optionally substituted heterocyclic diyl; B is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R¹ is a group such as optionally substituted lower alkyl; R² is a group such as hydrogen; and R^3a and R^3b are each independently a group such as hydrogen, provided that the following compound is excluded.

The invention discloses a method for preparing minodronate, which comprises the following steps of: condensing a compound II and a compound III to form a compound IV, closing rings of the compound IV and 2-aminopyridine to obtain a compound V, hydrolyzing the compound V into a compound VI, and finally performing phosphonation to form a compound I. The method avoids using virulent chemical reagents such as sodium cyanide or bromine and the like, has mild and controllable reaction condition, short reaction step, high yield and low cost, and is suitable for industrialized production.

The invention relates to a synthetic method of ceftazidime intermediate; 7-amino cephalsporanic acid is used as a raw material; a silanization reaction, an iodination reaction, and a pyridine reaction are performed; the obtained product is added with an oxidant, and hydrochloric acid or is added into a mixed solvent of an organic solvent and water to prepare a halogen acid salt of the ceftazidimeintermediate (6R, 7R)-7-amino-3-pyridine methyl-ceph-3-ene-4-carboxylic acid. The invention also provides a method for preparing ceftazidime by using the obtained intermediate halogen acid salt. The ceftazidime intermediate and ceftazidime prepared by the methods have high yield, and low production cost; the operation is simple; the discharge of three wastes is less; treatment and recovery are easy, and the methods are applicable to industrial production.

The invention discloses a preparation method of two-dimension nitrogen- and phosphorus-doped graphene. The preparation method particularly includes following steps: adding hydrotalcite to a proper amount of a sodium butyrate solution, stirring the mixture, aging the mixture, adding 4-dimethyl aminopyridine and n-butyl phosphate, stirring the mixture in a constant-temperature water bath at 60-70 DEG C for 6-8 h, separating a precipitation from liquid, washing the precipitation with deionized water for 2-3 times, drying and grinding the precipitation, sieving the precipitation through a sieve being 20-40 in meshes to obtain modified hydrotalcite powder, heating the modified hydrotalcite powder in a vacuum tubular furnace to 400-600 DEG C under a vacuum condition for calcining the powder for 2-4 h, adding the calcined powder to a hydrochloric acid solution, separating the precipitation and finally heating the precipitation to 2000-2500 DEG C under the vacuum condition to perform heat treatment for 3-6 h, and cooling a product to obtain the two-dimension nitrogen- and phosphorus-doped graphene. The preparation method is simple in raw materials and is mild in conditions.

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

The invention relates to a targeted polymer medicament carrier and a preparation method and application thereof. The targeted polymer medicament carrier has a molecular structural formula shown in the graph. The preparation method comprises the following steps of: a) feeding Pluronic and Biotin in a molar ratio of 1:1.1-1.5; dissolving the mixture in dichloromethane; adding 4-dimethylamino pyridine; dropwise adding 1,3-dicyclohexyl carbodiimide in an ice water bath; reacting at room temperature for 24 to 48 hours; extracting reactive fluid with 10 to 15 percent NaHCO3; freezing over night; filtering to remove undissolved substances; concentrating the reactive fluid; dropping the reactive fluid into cold absolute ethyl ether; filtering, and drying in vacuum; and b) dissolving a product with dry toluene, and distilling the product in the presence of argon gas; dehydrating by an azeotropy method; cooling to the room temperature; adding lactide according to 50 to 90 percent of the weight of the product in the presence of the argon gas, and adding stannous octoate according to 0.1 to 0.15 percent of the weight of the lactide; heating to the temperature of between 120 and 140 DEG C; reacting for 6 to 8 hours under stirring; immersing a reactant into the cold ethyl ether, and filtering; and dissolving polymer by using dichloromethane, immersing into methanol, and filtering and drying. The carrier can be used as carriers of medicaments for treating and diagnosing cancers.

The invention relates to the field of pharmaceutical chemistry, in particular to a synthesis method of a minodronate midbody and synthesis of minodronate. The preparation method of minodronate includes the following steps: using organic solvent to dissolve 2-aminopyridine, adding 4-acetyl chloride ethyl acetoacetate for reaction, monitoring the reaction solution by TLC(Thin-Layer Chromatography) until spots of 4-acetyl chloride ethyl acetoacetate disappear, concentrating to a dry state, dissolving concentrate in water, washing a water layer to remove impurities, extracting the water layer with the organic solvent, washing extract liquor, separating out an organic layer, conducting filtration, and concentrating the concentrate to be in a dry state, thereby obtaining A1.

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

The invention relates to a crystal form of a benzoylaminopyridine derivative, and an application of the crystal form, and also relates to a pharmaceutical composition containing the crystal form, andan application of the crystal form or the pharmaceutical composition in the preparation of drugs for preventing, treating or alleviating ASK1-regulated diseases of patients.

The invention belongs to the technical field of new drug synthesis, and in particular relates to an IDO inhibitor containing (E)-4-(beta-bromovinyl)phenoxy acyl structure, as well as a preparation method thereof. The preparation method comprises the following steps: solvent benzene, (E)-4-(beta-bromovinyl) phenol, carboxylic acid and p-dimethylaminopyridine are added to a flask respectively and magnetically stirred for 5 to 20 minutes at room temperature; then N, N'-dicyclohexylcarbodiimide is added and reacts for 2 to 24 hours at room temperature; after the reaction is completed, the solvent benzene is steamed off after decompression; residue is subjected to column chromatography separation and purification by taking ethyl acetate/petroleum ether as leacheate, and then a needed product can be obtained, wherein the molar ratio of the solvent benzene to the (E)-4-(beta-bromovinyl) phenol is 50-200:1; the molar ratio of the carboxylic acid to the (E)-4-(beta-bromovinyl) phenol is 1-1.5:1; the molar ratio of the p-dimethylaminopyridine to the (E)-4-(beta-bromovinyl) phenol is 0.1-1.5:1; and the molar ratio of the N, N'-dicyclohexylcarbodiimide to the (E)-4-(beta-bromovinyl) phenol is 1-1.2:1. The method takes the (E)-4-(beta-bromovinyl) phenol as a synthesis building block and obtains a series of the novel IDO inhibitors containing the (E)-4-(beta-bromovinyl)phenoxy acyl structure through esterification reaction, and the IDO inhibitors can be used for treating the diseases with the pathological features of IDO mediated tryptophan metabolic pathway.

The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. 1 In the formula, R.sup.1 represents hydrogen atom, a halogen atom or cyano group; R.sup.2 and R.sup.3 are the same as or different from and each represents hydrogen atom, a C.sub.1-C.sub.4 lower alkyl group or a halogen atom; R.sup.4 represents hydrogen atom or a C.sub.1-C.sub.4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R.sup.1, R.sup.2 and R.sup.3 are hydrogen atoms, where both R.sup.2 and R.sup.3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R.sup.1 and R.sup.2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R.sup.1 is cyano group or a halogen atom, at least one of R.sup.2 and R.sup.3 should not be a hydrogen atom.

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I):

[wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.

The invention relates to a method for preparing ceftazidime. The synthesis method comprises the following steps: by taking 7-aminocephalosporanic acid (7-ACA) as a starting raw material, introducing a pyridine ion to 3-position methylene of 7-ACA so as to obtain 7-amino-3-(1-picolyl)-cephem acid (7-APCA) hydrochloride; then introducing a side chain with a thiazole ring on 7-position amino of the 7-APCA hydrochloride through acylation reaction; and carrying out hydrolyzing reaction, refining reaction and the like so as to obtain ceftazidime. The synthesis method for preparing the ceftazidime inthe invention is simple to operate and high in yield, and is suitable for industrial production.

The invention relates to a preparation method of aminopyridine modified resin, which comprises the steps of allowing high polymer resin to swell in an organic solvent under backflow, adding an aminopyridine compound with a charge ratio of (1-7):1 to the high polymer resin, and an acid-binding agent at a mole ratio of (1-5):1 to the aminopyridine compound, allowing a mixed reaction system to react for 2-24h at 45-70 DEG C under a stirring condition to form the aminopyridine modified resin, separating, washing sequentially with water, alcohol, acetone and ether, and airing to form the aminopyridine modified resin of which a functional group content is 2.9-4.0mmol FG/g. The method is simple to operate, short in reaction time and convenient in preparation, and the modified resin can be independently used or filled as an adsorbing column, has good adsorbability for metal, particularly rhodium octanoate dimer in industrial waste water, and metal ions, particularly noble metal ions, and has important applications in environmental protection, analytical chemistry, metal ion extraction from waste liquid and the like.

An herbicidal composition containing (a) propyzamide and (b) aminopyralid provides synergistic control of selected weeds in oilseed rape and in broadleaf, grass and perennial crops.

The invention relates to a pyridylurea biquaternary ammonium salt as well as a preparation method and application thereof. The preparation method of the pyridylurea biquaternary ammonium salt comprises the following steps: using 3-aminopyridine as a staring material, conducting reaction on 3-aminopyridine and triphosgene to obtain 1,3-bi(3-pyridyl)urea, and conducting reaction on 1,3-bi(3-pyridyl)urea and alkyl bromide under the solvent-free condition to prepare the pyridylurea biquaternary ammonium salt. According to the method, a solvent-free method is adopted to prepare the pyridylurea biquaternary ammonium salt, so that the environment can be protected, and the yield is relatively high. The provided pyridylurea biquaternary ammonium salt can be used as a plant growth regulator to promote plant cell division, and the problem that the traditional phenylurea plant growth regulator is poor in water solubility is solved.

The invention relates to a preparation method for poly(2,5-dihydroxyl-1,4-phenylene pyridobisimidazole). The preparation method is realized by the following synthetic method: 2,3,5,6-tetraminopyridine (TAP) hydrochloride and 2,5-dihydroxyl-terephthalic acid (DHTA) are used as raw materials to carry out salificaton by an acid-base neutralization reaction so as to obtain 2,3,5,6-tetraminopyridine-2,5-dihydroxyl-terephthalate composite salt (TD salt); then high molecular weight PIPD fibers are prepared by temperature programmed solution polymerization in a polyphosphoric acid (PPA) system. The method solves the problems of low molecular weight and harsh polymerization conditions of a conventional method, aiming at the difficulties that amino groups are easily oxidized and equimolar ratio reaction can be kept in a whole process. The TD salt obtained by the process for synthesizing the 2,5-dihydroxyl-terephthalc acid-2,3,5,6-tetraminopyridine (TD) composite salt is stable in quality and easy to store; the polymerization reaction combines the advantages of a direct method and a TD salt method, so that the PIPD polymer with higher molecular weight is obtained without changing polymerization environment and polymerization equipment.